In mutant KRAS-driven murine models of NSCLC, genetic deletion of PTPN11 suppressed tumor development, while the dual inhibition of SHP2 and MEK resulted in sustained tumor growth control in murine- and human patient-derived organoids and xenograft models of NSCLC [103]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.